Research programme: c-Met inhibitors - Pfizer

Drug Profile

Research programme: c-Met inhibitors - Pfizer

Alternative Names: 448101; PF 425644; PHA-665752; SU-MI-2; SU11274

Latest Information Update: 15 Sep 2010

Price : $50

At a glance

  • Originator Pfizer
  • Class Heterocyclic bicyclo compounds; Pyridazines; Quinolines; Small molecules; Triazoles
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Sep 2010 Pharmacodynamics data from a preclinical trial in Kidney disorders
  • 03 Aug 2009 Preclinical development is ongoing in USA
  • 21 Aug 2008 Pharmacodynamics and pharmacokinetics data from preclinical trials in Cancer presented at the 236th National Meeting of the American Chemical Society (ACS-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top